Plain-English translation of NCT07571486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This early-stage trial is testing a device called the SC4 that uses focused ultrasound to temporarily open the blood-brain barrier — a protective layer around the brain that normally blocks most medicines from entering. The researchers believe that by opening this barrier repeatedly, they may be able to help medicines reach brain cells more effectively and also activate the immune system to fight ALS naturally.
One of the biggest challenges in treating ALS is that most medicines cannot cross the blood-brain barrier to reach the parts of the brain affected by the disease. This trial explores whether ultrasound can safely overcome this barrier, potentially opening a new way to deliver treatments directly to where they are needed most.
You likely qualify if…
You likely don't qualify if…
You would have an implantable ultrasound device surgically placed in your brain under local anesthesia at a hospital. After a 2-week recovery, you would return for repeated ultrasound treatment sessions (likely as an outpatient). Throughout the trial, you would have regular clinical visits to check your muscle strength, breathing, and quality of life, along with blood tests and brain imaging scans. The trial involves a 12-week run-in period before implantation and then ongoing monitoring visits over several months.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
France